Healthcare Group: 2020 Year In Review
- January 7, 2021
Oppenheimer’s Healthcare Banking Team Had a Record Year in 2020
Despite COVID-19 headwinds, Oppenheimer Healthcare continued its strong growth trajectory driven by great steps taken in our bookrun equity franchise. Bookrun deal volume increased 73% in 2020 and average bookrun deal size increased 50%.
Leading Provider of Investment Banking Services to International Companies
Oppenheimer has continued to be one of the most active middle market banks on Wall Street for international companies accessing the U.S. market.
2020 Oppenheimer Bookrun Healthcare Financings
Oppenheimer raised over $1.8B in 45 bookrun transactions in 2020
Additional 2020 Healthcare Financings
Oppenheimer was involved in an additional 38 financings raising over $6.1B in 2020.
Throughout 2020 we hosted several thought provoking virtual events and conferences, and we look forward to many more in 2021.
Michael A. Margolis, R.Ph.
Title:Co-Head of Healthcare, Head of Healthcare Life Sciences
DISCLOSURE
THIS DOCUMENT IS FOR DISCUSSION PURPOSES ONLY AND DOES NOT CONSTITUTE ADVICE OF ANY KIND, INCLUDING TAX, ACCOUNTING, LEGAL OR REGULATORY ADVICE, AND OPPENHEIMER & CO. INC. IS NOT AND DOES NOT HOLD ITSELF OUT TO BE AN ADVISOR AS TO TAX, ACCOUNTING, LEGAL OR REGULATORY MATTERS.
THE INFORMATION CONTAINED HEREIN WAS OBTAINED FROM PUBLIC SOURCES AND WAS RELIED UPON BY OPPENHEIMER & CO. INC. WITHOUT ASSUMING RESPONSIBILITY FOR INDEPENDENT VERIFICATION AS TO THE ACCURACY OR COMPLETENESS OF SUCH INFORMATION. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, IS MADE AS TO THE ACCURACY OR COMPLETENESS OF SUCH INFORMATION AND NOTHING CONTAINED HEREIN IS, OR SHALL BE RELIED UPON AS, A REPRESENTATION OR WARRANTY, WHETHER AS TO THE PAST OR THE FUTURE.
OPPENHEIMER & CO. INC. ASSUMES NO OBLIGATION TO UPDATE OR OTHERWISE REVISE THESE MATERIALS.
OPPENHEIMER & CO. INC.’S RESEARCH DEPARTMENT IS REQUIRED TO BE INDEPENDENT FROM ITS INVESTMENT BANKING DEPARTMENT, AND ITS RESEARCH ANALYSTS MAY HOLD AND MAKE STATEMENTS OR INVESTMENT RECOMMENDATIONS THAT DIFFER FROM THE VIEWS OF ITS INVESTMENT BANKERS. FURTHER, PURSUANT TO APPLICABLE LAW, OPPENHEIMER & CO. INC. IS (AMONG OTHER THINGS) PRECLUDED FROM OFFERING FAVORABLE RESEARCH, A SPECIFIC RATING OR A SPECIFIC PRICE TARGET, OR THREATEN TO CHANGE RESEARCH, A RATING OR A PRICE TARGET, AS CONSIDERATION OR INDUCEMENT FOR THE RECEIPT OF BUSINESS OR COMPENSATION.
OPPENHEIMER & CO. INC. TRANSACTS BUSINESS ON ALL PRINCIPAL EXCHANGES AND MEMBER SIPC 3393139.1.